Firmonertinib mesylate
Highest phase reached
Phase 1
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 1
- Drug type
- Small molecule
- Drug name
- Firmonertinib mesylate
- Molecular weight
- 664.71
- Structure (SMILES)
- C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OCC(F)(F)F)nc1N(C)CCN(C)C.CS(=O)(=O)O
- alflutinib mesilate
- Alflutinib mesilate
- alflutinib mesylate
- Alflutinib mesylate
- ast 2818 mesylate
- AST-2818 MESYLATE
- ast2818 mesylate
- AST2818 mesylate
- Firmonertinib mesilate [WHO-DD]
- firmonertinib mesilate who dd
- firmonertinib mesylate
- Firmonertinib mesylate
- FIRMONERTINIB MESYLATE [USAN]
- firmonertinib mesylate usan
- furmonertinib mesilate
- Furmonertinib mesilate
- furmonertinib mesilate tablets
- Furmonertinib Mesilate Tablets
- furmonertinib mesylate
- Furmonertinib mesylate
- ivesa
- Ivesa
- CAS registry numbers
- 2130958-55-1
- ChEMBL ID
- CHEMBL6068476
- InChIKey
- WDPGHXINXNBHAS-UHFFFAOYSA-N
- PubChem compound IDs
- 134828257
- FDA ingredient codes (UNII)
- Q09ZKD19V0
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -tinib
Open Targets mechanisms
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
- Action type
- Inhibitor
- Target
- Epidermal growth factor receptor
Investigated indications
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0008903
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0056806
- Highest recorded phase
- 2
Reported adverse events
- Event
- myelosuppression
- Reports
- 1
- Reporting signal score
- 5.60449
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 2
- Polar surface area
- 100.44
- Calculated partition coefficient (ALogP)
- 4.84
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 11
- Heavy atoms
- 46
- Molecular formula
- C29H35F3N8O5S
- Monoisotopic mass
- 664.24032191
- Natural product
- No
- Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES.
Related records
Trials (5)
- A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
- A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
- A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
- Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC
In development for (2)
- Lung cancer Phase 2
- Neoplasm Phase 1